Brief: Roche Strengthens Cancer Diagnostic Portfolio With Launch Of Test For Differential Diagnosis Of Mesothelioma
Yesterday 06:01
BRIEF-Roche Strengthens Cancer Diagnostic Portfolio With Launch Of Test For Differential Diagnosis Of Mesothelioma Oct 28 (Reuters) - ROCHE HOLDING AG ROPC.S:
ROCHE STRENGTHENS CANCER DIAGNOSTIC PORTFOLIO WITH LAUNCH OF TEST FOR DIFFERENTIAL DIAGNOSIS OF MESOTHELIOMA
ROCHE HOLDING AG - VENTANA BAP1 (SP527) PROVIDES ACCURATE MESOTHELIOMA DIAGNOSIS AND DIFFERENTIATION
ROCHE HOLDING AG - BAP1 ASSAY REGISTERED AS CLASS I IVD WITH FDA AND RECEIVED IVDR CLASS C APPROVAL
ROCHE HOLDING AG - BAP1, MTAP, CLAUDIN-4 TESTS ENABLE ACCURATE CANCER DIFFERENTIATION AND MINIMIZE TISSUE LOSS
Source text: ID:nGNE7g1pM4
Further company coverage: ROPC.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))